{"id":499182,"date":"2010-04-01T07:56:39","date_gmt":"2010-04-01T11:56:39","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=71249"},"modified":"2010-04-01T07:56:39","modified_gmt":"2010-04-01T11:56:39","slug":"isis-snags-glaxo-deal-orexigen-heads-to-fda-cyntellect-pockets-3m-more-san-diego-area-life-sciences-news","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/499182","title":{"rendered":"Isis Snags Glaxo Deal, Orexigen Heads to FDA, Cyntellect Pockets $3M & More San Diego Area Life Sciences News"},"content":{"rendered":"\n
Roundup<\/a>, Biotech<\/a>, people<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

This week I traveled here for Xconomy’s big event on the 20-year future for San Diego’s life sciences cluster. My wrap-up on that event is probably going to have to wait until Friday, but there was plenty of other news from San Diego biotech to keep the site buzzing.<\/p>\n

—Carlsbad, CA-based Isis Pharmaceuticals<\/strong> (NASDAQ: ISIS<\/a>) struck a big deal this week with GlaxoSmithKline<\/a>. Isis will pocket $35 million upfront, and could stand to rake in as much as $1.5 billion if it hits every milestone for all six drug development programs covered under the deal. Of course, that’s unlikely, but even in “biodollars” that’s no small deal.<\/p>\n

—San Diego-based Orexigen Therapeutics<\/strong> (NASDAQ: OREX<\/a>) has formally asked the FDA to clear its first product for sale<\/a> in the U.S. Orexigen’s new drug application is for a combination of bupropion and naltrexone (Contrave), which it says has been studied in more than 4,500 people. If Orexigen wins FDA approval, it could be following fast behind a couple other rivals—San Diego-based Arena Pharmaceuticals, and Mountain View, CA-based Vivus.<\/p>\n

—San Diego-based Somaxon Pharmaceuticals<\/strong> (NASDAQ: SOMX<\/a>) has been riding a wave of enthusiasm since it won FDA approval for its insomnia drug, but as Denise points out in this follow-up story, the hard job of commercialization begins now.<\/a><\/p>\n

—A couple of small venture financings crossed our biotech desk this week. Biocept<\/strong>, a San Diego biotech company developing cell separation technology, has raised $3.6 million<\/a> out of a $4 million round, according to a regulatory filing. The SEC filings also showed that Cyntellect<\/strong>, a San Diego-based company working on technologies to analyze, purify and process cells, raised $3 million<\/a> from the sale of debt, equity and options or warrants.<\/p>\n

—Richard Pops<\/strong>, the CEO of Waltham, MA-based Alkermes (NASDAQ: ALKS<\/a>), offered up a guest editorial<\/a> on a relevant issue for biotechies all over the country—the renewal of the Prescription User Fee Act that governs relations between drugmakers and the FDA. Pops’s company has a major connection to San Diego, because it provides key enabling technology to Amylin Pharmaceuticals<\/strong>‘ exenatide once-weekly treatment for diabetes.<\/p>\n

—”Cost-effectiveness” is a term we’re all going to hear more in years to come because of healthcare reform, and Denise nailed a timely profile<\/a> of a San Diego company that is looking to seize on that trend. NextImage Medical<\/strong> is seeking to increase the efficiency of radiology exams, which is one of the culprits driving up the cost of worker’s compensation premiums in California.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Roundup, Biotech, people Luke Timmerman wrote: This week I traveled here for Xconomy’s big event on the 20-year future for San Diego’s life sciences cluster. My wrap-up on that event is probably going to have to wait until Friday, but there was plenty of other news from San Diego biotech to keep the site buzzing. […]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-499182","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/499182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=499182"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/499182\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=499182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=499182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=499182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}